Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.070 +0.190 (+6.60%)
Streaming Delayed Price Updated: 2:26 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
ROSEN, A RANKED AND LEADING FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
WHY: NEW YORK, NY - (NewMediaWire) - May 12, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune,... 
Via TheNewswire.com
Topics Lawsuit
News headline image
ROSEN, A LEADING NATIONAL FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, A LEADING NATIONAL FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
WHY: NEW YORK, NY - (NewMediaWire) - May 11, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune,... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action
From Robbins LLP
Via Business Wire
News headline image
ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 ↗
ALT stock results show that Altimmune beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
WHY: NEW YORK, NY - (NewMediaWire) - May 10, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune,... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Peering Into Altimmune's Recent Short Interest ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Altimmune? ↗
 
Via Benzinga
News headline image
ALT INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025 ↗
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
News headline image
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Altimmune, Inc. (ALT)
From Robbins LLP
Via GlobeNewswire
News headline image
Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit
From Block & Leviton LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From Rosen Law Firm
Via Business Wire
News headline image
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Jim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment' ↗
Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money." 
Via Benzinga
News headline image
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains ↗
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
News headline image
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
News headline image
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential ↗
Altimmune has a modest market cap but an incredibly promising GLP-1 drug. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 ↗
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
News headline image
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead. ↗
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate. 
Via The Motley Fool
News headline image
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.